dipyridamole has been researched along with Bullous Dermatoses in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with dipyridamole and aspirin correlated with reversal of these abnormalities and cessation of new lesion development." | 1.28 | Malignant atrophic papulosis: response to antiplatelet therapy. ( Drucker, CR, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drucker, CR | 1 |
1 other study available for dipyridamole and Bullous Dermatoses
| Article | Year |
|---|---|
Malignant atrophic papulosis: response to antiplatelet therapy.
Topics: Adult; Aspirin; Biopsy; Dipyridamole; Humans; Male; Platelet Aggregation Inhibitors; Skin Diseases, | 1990 |